EverlyWell’s partner labs are the same laboratories used by hospitals and physicians around the US, maintaining the same standards of quality and excellence as hospital labs. Each lab we partner with is CLIA-certified by the federal government, which means they must meet high precision, accuracy, and validity standards, obtain both state and federal certifications, and submit themselves to regular inspections as well as independent third-party performance verifications.
Our collection methods are effective, well-established, and easy to do at home. We only offer collection methods that meet rigorous standards for reliability, stability, and validity for use in at-home collection.
It’s a common misconception that labs need entire vials of blood to run one or more tests. In reality, many common tests can be done with only a small amount of blood, and there is often a large amount of wasted and unused sample left after testing is complete.
For each test, our medical team curates the biomarkers we think are the most useful and applicable to providing the health insights you care about. These test results are meant to help you understand your health and well-being, and to provide you with data and options to make dietary or lifestyle changes. Our tests are generally the same tests that your physician orders, and are supported by independent, peer-reviewed research.
We always encourage sharing your EverlyWell results with your healthcare provider. You can print or email a “doctor friendly” version of your results in a format that your physician is used to seeing when normally reviewing lab results. Our tests provide personalized information and education that empowers you to be more involved with and educated about your own health. But, our tests are not intended to diagnose diseases (with the exception of our STD test offerings). You should always seek the advice of your physician or other qualified healthcare provider with any questions you have regarding your medical care.
EverlyWell conducts original clinical research to inform the medical and scientific community, engage customers in their healthcare journey, and further our understanding of how our community utilizes our products to improve their health and wellness. Our research is guided by the latest approaches to nutrition, heart health, gender-specific wellness, and sexual wellness. We incorporate clinical and data science best practices to understand complex, real world data.
Presented at NIH Conference: Sleep and the Health of Women, October 16-17, 2018
Women Aged 50 and Older Have a Significantly Lower Early Morning Urinary 6-Sulfatoxymelatonin (MT6) Level than Women Under age 50 in a Consumer-initiated At-home Sleep Test.
Background
MT6 is the sulfated conjugate of the primary metabolite of melatonin. A first void of the day urinary measurement of MT6 is a reliable indicator of overnight melatonin production.
Objectives
To examine first morning void urinary levels of MT6 in women and determine if there are any significant differences in mean levels based on age alone.
Methods
De-identified data was obtained using SQL queries of EverlyWell’s database for women who took a Sleep and Stress test from May 2016 through July 2018. A total of 299 women received Sleep and Stress test results during this time period. Our analysis excluded women who had a “less than detectable limit” result or women who had greater than two times the upper limit for normal first morning void MT6 levels which suggests exogenous melatonin supplementation.
Results
A total of 200 women aged 25-73 had early morning MT6 levels that met the criteria for inclusion in the study. The CLIA certified partner lab reports a normal early morning MT6 range for women of 18.0-40.9 ng/mL with a mean of 29.45 ng/mL. The analysis showed that 140 women under age 50 had a mean first void MT6 level of 34.72 ng/mL, while women aged 50 and older had a mean of 25.68 ng/mL.
Conclusions
EverlyWell is not only the market leader in the consumer-initiated, at-home lab testing space, but we also strive to be a thought leader in the clinical community. For our published research, we always anonymize, de-identify and aggregate data and seek supplemental data from our customer for more qualitative aspects on an opt-in, voluntary basis only. Customer information is only shared with the third-party lab and physicians that are part of our testing process. Under no circumstance do we ever sell our customers' data, and we use state-of-the-art, bank grade encryption to ensure data security. Check out our full privacy policy for more details.
ACOG - To be Presented at National Meeting May 2019
Results from Comprehensive STD Testing in Women Utilizing an At-Home Kit Over Twelve Months
Introduction
This data set review examined rates of positive sexually transmitted disease (STD) results in women utilizing a consumer-initiated, self-collected STD kit over a twelve-month period.
Methods
De-identified data was obtained using SQL queries of EverlyWell’s database for women who took a Women’s STD Panel Test from September 2017 through September 2018. A total of 1,002 women received results, 51 were excluded for having an inconclusive or equivocal result, and 951 results were analyzed in this study. The age range of women in this data set were 18 to 76.
Results
Overall, 21% of women received at least one positive STD result and 1.8% received more than one positive result. The most common STD resulted was Herpes Simplex Type 2 at 18%, followed by Chlamydia trachomatis at 3%. The largest age group utilizing this platform for testing was 25 to 29 years, compromising 23% of total tests taken. The highest proportion of positives within a single age group was found in 55 to 59 years; 56% of the total women in that group received a positive result.
Conclusions
At-home STD testing may allow women who would otherwise potentially be under-screened for a variety of reasons to easily manage their sexual health testing. Despite 55 to 59-year old women compromising only 2.8% of the total test takers in this data set, 56% of women in that cohort received a positive STD result. STD testing at home can easily be utilized by women of all ages to identify infections between routine gynecological visits.
EverlyWell is not only the market leader in the consumer-initiated, at-home collection lab testing space, but we also strive to be a thought leader in the clinical community. For our published research, we always anonymize, de-identify and aggregate data. We seek supplemental data from our customers for more qualitative aspects on an opt-in, voluntary basis only. Customer information is only shared with the third-party lab and physicians that are part of our testing process. Under no circumstance do we ever sell our customers' data, and we use state-of-the-art, bank grade encryption to ensure data security. Check out our full privacy policy for more details.